In a groundbreaking advance poised to transform the landscape of age-related immune decline, University College London (UCL) researchers are spearheading a pioneering clinical trial aimed at rejuvenating worn-out T cells through an innovative immune restoration therapy. This Phase 1 first-in-human study will explore the therapeutic potential of metabolically resetting exhausted or senescent T cells, a subset of immune cells that accumulate with age and chronic disease and lose their robustness in coordinating immune responses. The initiative promises to reopen avenues for combating a spectrum of diseases, including cancer, HIV, and neurodegenerative disorders like dementia, by profoundly modifying the immune system’s intrinsic capacity to defend and repair.

Central to the research is the recognition that immune ageing, characterized by the progressive dysfunction and decline in immune cell performance, is a key factor leading to increased vulnerability in the elderly and those with chronic infections. T cells, particularly the CD4+ subtype—often regarded as the conductors of the immune orchestra—become less effective with time, diminishing the immune system’s ability to coordinate defenses accurately. These cells, rendered senescent or exhausted, exhibit impaired proliferation, cytokine production, and cytotoxic activity, undermining responses to pathogens, malignancies, and cellular damage.

The novel therapy, developed by SenTcell, a biotech startup founded by Dr. Alessio Lanna from UCL Medicine, employs a liquid formulation administered intramuscularly akin to conventional vaccines. This delivery method facilitates patient-friendly administration while targeting key metabolic pathways within dysfunctional T cells. By reprogramming the intracellular environment of these immune cells, the treatment aims to restore youthful functional properties, including enhanced proliferative capacity and efficient pathogen recognition, thereby revitalizing the immune system’s broad protective functions.

Dr. Lanna explains that although antiretroviral advancements have significantly improved lifespans for individuals living with HIV, many still experience premature immune ageing. Similar patterns of immune exhaustion are also detected in cancer patients and other chronic disease cohorts. The imminent clinical trial represents a critical stepping stone towards verifying whether exhausted immune cells can be safely and effectively rejuvenated in human subjects, with the potential to redefine therapeutic paradigms for diseases rooted in immune dysregulation.

At the molecular level, one of the intriguing aspects under investigation involves the role of telomeres—protective caps on chromosome ends whose shortening serves as a hallmark of biological ageing. Laboratory studies have suggested that rejuvenated CD4+ T cells may release telomere-containing extracellular structures, whimsically termed “telomere Rivers,” into the bloodstream. The presence and behavior of these structures might offer novel insights into how restored immune cells influence systemic health, extending their benefits beyond immediate immune niches to broader tissue health. Although this phenomenon has yet to be validated in human clinical contexts, it highlights the sophisticated interplay between immune rejuvenation and organismal aging.

The clinical trial enjoys regulatory support from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) through its Innovative Licensing and Access Pathway (ILAP), underscoring the therapy’s potential to meet the pressing unmet medical needs associated with immune senescence. This endorsement accelerates development timelines and affirms the significance of targeting immune metabolic dysfunction as a viable therapeutic strategy.

Participants in the upcoming Phase 1 trial will be meticulously selected adults exhibiting characteristics of immune dysfunction, including evidence of premature immune ageing or persistent viral infections. Comprehensive immune profiling will be conducted before and after therapeutic administration to discern immunological changes and safety outcomes. Although the initial focus is on evaluating biological activity and tolerability, successful results could pave the way for advanced trials assessing clinical efficacy.

Unlike conventional treatments that combat diseases by targeting individual pathogens or tumor cells directly, this therapy seeks to recalibrate the immune system itself—restoring its intrinsic resilience and regenerative functionality. Such a paradigm shift holds profound implications; by enhancing the immune system’s natural defensive repertoire, it may afford broad-spectrum protection and facilitate healthier ageing trajectories.

Beyond chronic infections like HIV and cancer, this approach could ultimately apply to autoimmune disorders characterized by immune exhaustion, wherein overly active yet dysfunctional immune cells drive pathology. Immune rejuvenation strategies offer a novel means of restoring balance without broadly suppressing immune activity, potentially mitigating disease progression while improving quality of life.

This research aligns with a growing global focus on understanding the cellular and molecular underpinnings of ageing and immune decline. By intervening at the level of T cell metabolism and function, scientists hope to extend not only lifespan but healthspan—preserving cognitive and physical function while reducing susceptibility to infections, cancer, and degenerative diseases.

As UCL celebrates two centuries of academic excellence and innovation, this project embodies the institution’s commitment to translating bold scientific ideas into therapies capable of reshaping medicine. If validated through clinical trials, this immune rejuvenation therapy could herald a transformative era in treating age-associated diseases, offering hope for millions affected by immune dysfunction worldwide.

Subject of Research: People
Article Title: Immune Rejuvenation: UCL’s Pioneering Trial Targets T Cell Exhaustion to Combat Age-Related Immune Decline
News Publication Date: Not provided
Web References: www.ucl.ac.uk
References: Not provided
Image Credits: Not provided
Keywords: Immune ageing, T cell exhaustion, CD4+ T cells, immune rejuvenation, senescent immune cells, telomeres, immune dysfunction, chronic disease, HIV, cancer, metabolic resetting, Phase 1 clinical trial

In a groundbreaking study published in Nature Communications, scientists have unveiled how a mitochondrial protein known as OPA3 plays a pivotal role in sustaining cardiac function by regulating calcium handling in male mice. This discovery sheds new light on the intricate cellular mechanisms that underpin heart performance and opens up promising avenues for treating cardiovascular diseases, which remain a leading cause of mortality worldwide. The findings emphasize the critical interplay between mitochondrial dynamics and calcium signaling within cardiac muscle cells, providing a fresh perspective on how cellular energy production influences heart health.

The heart’s ability to maintain rhythmic and efficient contractions is fundamentally dependent on the precise regulation of intracellular calcium levels. Calcium ions serve as essential second messengers in cardiac myocytes, triggering contraction through complex signaling cascades. However, the interplay between calcium dynamics and mitochondrial proteins, especially those involved in mitochondrial morphology and function, has remained elusive until now. The current study identifies the mitochondrial protein OPA3 as a key modulator in this regulatory network, maintaining both mitochondrial integrity and calcium homeostasis crucial for cardiac contractility.

OPA3 is traditionally recognized for its role in maintaining mitochondrial morphology, particularly in mitochondrial fission and fusion processes. These processes are vital for preserving the mitochondrial network’s dynamic nature, which is essential for cellular energy metabolism. Mitochondria not only produce ATP but also buffer intracellular calcium, thereby influencing calcium signaling within cardiac cells. By elucidating how OPA3 influences calcium handling, researchers have bridged an important gap between mitochondrial structural proteins and the functional output of cardiac cells.

Experimental models using male mice engineered for OPA3 depletion revealed significant impairments in cardiac function, demonstrating that loss of OPA3 disrupts calcium cycling in cardiac myocytes. Impaired calcium handling directly correlates with diminished contractile force and defective cardiac output. This suggests that OPA3’s influence extends beyond structural maintenance and into functional regulation of calcium channels or transporters. The dysregulation of such a critical ion pathway can lead to arrhythmias and cardiac failure, underscoring the potential clinical significance of these findings.

At the molecular level, the study highlights that OPA3 affects the expression and activity of key calcium regulators including the sarcoplasmic reticulum Ca2+ ATPase (SERCA) and ryanodine receptors (RyR). These proteins govern calcium reuptake and release in cardiac cells, orchestrating contraction and relaxation cycles. Through advanced imaging and electrophysiological techniques, the research team demonstrated that OPA3 deficiency impairs SERCA function and causes aberrant RyR-mediated calcium leak, leading to calcium overload or deficits. Such pathophysiological alterations are known contributors to cardiac hypertrophy and heart failure in humans.

The investigation also explores the bioenergetic consequences of OPA3 modulation. Mitochondrial bioenergetics in cardiac muscle cells are highly tuned to meet the energy demands of continuous contractions. OPA3 deficiency was found to compromise mitochondrial ATP production by disrupting inner membrane potential and electron transport chain efficiency. These mitochondrial defects culminate in inadequate energy supply for calcium pumps and ion exchangers, further exacerbating contractile dysfunction. This uncovers a feedback loop where structural mitochondrial proteins like OPA3 indirectly regulate calcium handling by maintaining energetic homeostasis.

A remarkable aspect of the study lies in its use of state-of-the-art imaging techniques such as live-cell confocal microscopy and super-resolution electron microscopy, which revealed morphological abnormalities in mitochondria lacking OPA3. Fragmented and swollen mitochondria with disrupted cristae architecture were prevalent in OPA3-deficient cardiomyocytes. These structural derangements are likely responsible for the observed bioenergetic failures and altered calcium buffering capacity, collectively impairing the cardiomyocyte’s functional integrity.

Furthermore, the team utilized optogenetics-based calcium sensors to monitor real-time calcium flux in isolated cardiomyocytes, providing unprecedented insight into how OPA3 influences calcium transients during excitation-contraction coupling. Data revealed that OPA3 loss leads to prolonged calcium decay time and increased diastolic calcium levels, conditions that predispose cardiac cells to arrhythmic events and contractile inefficiency. These calcium handling anomalies could explain the pathophysiology of certain forms of cardiomyopathy linked to mitochondrial dysfunction.

Importantly, the study addresses the potential sex-specific roles of OPA3, noting that experiments were conducted exclusively in male mice to control for hormonal influences on cardiac physiology. This raises intriguing questions about whether OPA3 functions similarly in female models and whether sex hormones modulate its expression or activity. Such considerations are critical as sex differences in cardiovascular disease outcomes are well-documented, emphasizing the need for further research in this domain.

The translational implications of these findings are profound. Therapeutic strategies aimed at restoring or enhancing OPA3 function could stabilize mitochondrial morphology and bioenergetics, thereby normalizing calcium handling and improving cardiac contractility. Such interventions might hold promise for treating heart failure syndromes characterized by mitochondrial and calcium dysregulation. Moreover, identifying small molecules or gene therapies targeting OPA3 pathways might complement existing treatments that primarily focus on calcium channels but neglect mitochondrial contributions.

Beyond the heart, the role of OPA3 in mitochondrial dynamics suggests potential relevance in other tissues with high energetic demand, such as skeletal muscle and the brain. Defects in mitochondrial morphology and calcium handling have been implicated in neurodegenerative diseases and metabolic disorders. Thus, understanding OPA3’s function could have broad implications in diverse biomedical fields, making it a protein of significant interest in physiology and pathophysiology.

This study also raises several compelling scientific questions for future research. How does OPA3 interact with other mitochondrial fission and fusion proteins, such as OPA1, MFN1/2, and DRP1, in regulating calcium signaling? What are the upstream regulators of OPA3 expression in cardiac tissue under physiological and pathological conditions? Additionally, can OPA3 modulation reverse established cardiac dysfunction or is it mainly preventive? Addressing these queries will deepen our understanding of cardiac mitochondrial biology and pave the way for novel therapeutic innovations.

Addressing cardiac diseases from a mitochondrial perspective represents a paradigm shift in cardiovascular medicine. Historically, calcium handling has been studied primarily through its direct regulators, but this research highlights the necessity of considering mitochondrial proteins like OPA3 as integral components of intracellular calcium homeostasis. This refined viewpoint may revolutionize how clinicians and scientists approach diagnosis, prognosis, and treatment of cardiac ailments.

In conclusion, the identification of mitochondrial protein OPA3 as a fundamental regulator of cardiac calcium handling marks a significant advance in cardiovascular biology. By elucidating the link between mitochondrial morphology, energy metabolism, and calcium signaling, this work provides critical insights into the molecular basis of cardiac function and dysfunction. It offers hope for innovative interventions that could alleviate the burden of heart disease, fostering improved patient outcomes and advancing the frontier of precision medicine in cardiology.

Subject of Research:
Mitochondrial protein OPA3 and its role in cardiac function via regulation of intracellular calcium handling mechanisms.

Article Title:
Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice.

Article References:
Geng, N., Chen, T., Li, H. et al. Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73991-4

Image Credits: AI Generated

Copper diacetyl bis(4-methyl-3-thiosemicarbazone), or Cu(ATSM), restored a key waste-removal system in the brain, reducing toxic amyloid-beta buildup and improving spatial memory in lab models of Alzheimer’s disease, according to a team of researchers at Monash University.

The post Experimental Copper-Based Drug Clears Alzheimer’s Plaques and Boosts Memory in Mice appeared first on Sci.News: Breaking Science News.

The glowing green nebula in this JWST image surrounds the star cluster IC 348, which is the subject of a recent study by Kevin Luhman (Penn State University) and Catarina Alves de Oliveira (European Space Agency). Using JWST’s Near-Infrared Camera, Luhman and Alves de Oliveira searched the cluster’s young stellar population for free-floating brown dwarfs — objects that are less massive than stars but more massive than most planets — and discovered multiple candidates with masses down to just twice the mass of Jupiter. Follow-up JWST spectroscopy confirmed the masses of these objects, making them the lowest-mass brown dwarfs known to date. In addition to their mass, these newly discovered brown dwarfs are remarkable because their spectra show evidence of hydrocarbon molecules, the exact identities of which are not yet known. Luhman and Alves de Oliveira proposed that low-mass brown dwarfs bearing this chemical signature be inducted into a new spectral class called “H” for “hydrocarbon.” To add to the intrigue of these objects, the authors also discovered signs of circumstellar disks around two of them, suggesting that they may be capable of forming and harboring planets. To learn more about the low-mass brown dwarfs in IC 348, be sure to check out the full research article linked below.

Citation

“A New Spectral Class of Brown Dwarfs at the Bottom of the IMF in IC 348,” K. L. Luhman and C. Alves de Oliveira 2025 ApJL 986 L14. doi:10.3847/2041-8213/addc55

The post Featured Image: Low-Mass Brown Dwarfs in a Class of Their Own? appeared first on AAS Nova.

In a podcast discussion, Dr. David E. Martin warns of a predicted bioterror attack on July 4, 2025, as outlined in the “National Blueprint for Biodefense” report, which anticipates 200,000 animal and 280,000 human casualties in one day. He compares it to the prior Event 201 exercise related to COVID-19, urging public alertness.